Studying new antibiotics for multidrug resistant infections: are today's patients paying for unproved future benefits?

BMJ. 2018 Feb 22:360:k587. doi: 10.1136/bmj.k587.

Authors

John H Powers¹, Scott R Evans², Aaron S Kesselheim³

Affiliations

¹ George Washington University School of Medicine, Washington, DC, USA.
² Department of Biostatistics and the Center for Biostatistics in AIDS Research, Harvard T H Chan School of Public Health, Boston, MA, USA.
³ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA.

PMID: 29472192
DOI: 10.1136/bmj.k587

No abstract available

MeSH terms

Anti-Bacterial Agents / therapeutic use*
Bacterial Infections / drug therapy*
Drug Approval
Drug Resistance, Multiple, Bacterial*
Forecasting
Humans
United States
United States Food and Drug Administration

Substances

Anti-Bacterial Agents